Pfizer (PFE) Stock Forecast & Price Target $25.92 +0.02 (+0.07%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$25.91 -0.01 (-0.03%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Pfizer - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating HoldBased on 21 Analyst RatingsSell3Hold12Buy6 Based on 21 Wall Street analysts who have issued ratings for Pfizer in the last 12 months, the stock has a consensus rating of "Hold." Out of the 21 analysts, 3 have given a sell rating, 12 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for PFE. Consensus Price Target $28.6110.39% Upside According to the 21 analysts' twelve-month price targets for Pfizer, the average price target is $28.61. The highest price target for PFE is $36.00, while the lowest price target for PFE is $25.00. The average price target represents a forecasted upside of 10.39% from the current price of $25.92. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for PFE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Pfizer and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PFE Analyst Ratings Over TimeTypeCurrent Forecast5/25/25 to 5/25/261 Month Ago4/25/25 to 4/25/263 Months Ago2/24/25 to 2/24/261 Year Ago5/25/24 to 5/25/25Strong Buy1 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)Buy5 Buy rating(s)6 Buy rating(s)4 Buy rating(s)5 Buy rating(s)Hold12 Hold rating(s)14 Hold rating(s)14 Hold rating(s)12 Hold rating(s)Sell3 Sell rating(s)3 Sell rating(s)2 Sell rating(s)1 Sell rating(s)Consensus Price Target$28.61$28.48$27.84$28.74Forecasted Upside10.39% Upside5.44% Upside2.60% Upside23.15% UpsideConsensus RatingHoldHoldHoldHold PFE Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History PFE Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Pfizer Stock vs. The CompetitionTypePfizerMedical CompaniesBroader MarketConsensus Rating Score 2.19 2.30 2.52Consensus RatingHoldHoldModerate BuyPredicted Upside10.39% Upside1,714.95% Upside15.09% UpsideNews Sentiment RatingPositive NewsSee Recent PFE NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails5/14/2026 Wolfe Research3 of 5 stars Reiterated RatingUnderperform$26.00+0.17%5/6/2026 Weiss RatingsNot Rated UpgradeHold (C-) ➝ Hold (C)4/29/2026 Citigroup4 of 5 starsGeoff Meacham5 of 5 starsBoost TargetNeutral$26.00 ➝ $27.00+2.10%4/20/2026 Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingTrung HuynhSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingUnderperform$25.00-9.33%4/16/2026 CICC ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJin ZhangSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageOutperform$33.00+21.31%4/13/2026 UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMichael YeeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetNeutral$25.00 ➝ $27.00-1.19%4/10/2026 Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingTerence FlynnSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetEqual Weight$27.00 ➝ $28.00+3.65%4/9/2026 Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJason GerberrySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetNeutral$27.00 ➝ $26.00-5.08%3/24/2026 GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingVamil DivanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$35.00 ➝ $36.00+34.47%3/17/2026 HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingRajesh KumarSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$29.00 ➝ $32.00+18.06% Get the Latest News and Ratings for PFE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter. 3/9/2026 BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEvan David SeigermanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOutperform$30.00+12.32%3/2/2026 ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid ToungSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeHold ➝ Buy$35.00+26.78%2/24/2026 Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeStrong Sell ➝ Hold2/19/2026 BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEmily FieldSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageEqual Weight ➝ Underweight$25.00-6.96%2/12/2026 Daiwa Securities GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating DowngradeOutperform ➝ Neutral$27.00-1.69%2/4/2026 Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingCarter GouldSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingNeutral$27.00+1.02%12/30/2025 TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingHold11/13/2025 ScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Initiated CoverageSector Outperform$30.00+14.08%11/5/2025 The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAsad HaiderSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingNeutral$26.00+7.06%10/31/2025 Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingCourtney BreenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingMarket Perform$30.00+22.88%5/29/2025 Berenberg BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetHold$28.00 ➝ $25.00+6.66%5/21/2025 Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetBuy$32.00 ➝ $33.00+43.11%4/30/2025 Rothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetNeutral$29.00 ➝ $27.00+10.61%4/30/2025 Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetMarket Perform$28.00 ➝ $26.00+6.51%12/18/2024 Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetBuy$36.00 ➝ $32.00+21.72%10/30/2024 EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingU. RaffatSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy7/31/2024 Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetEqual Weight$28.00 ➝ $30.00-3.23%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 01:53 AM ET. Should I Buy Pfizer Stock? PFE Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, May 21, 2026. Please send any questions or comments about these Pfizer pros and cons to contact@marketbeat.com. Pfizer Bull Case Here are some ways that investors could benefit from investing in Pfizer Inc.: Recent analyst upgrades have raised the price target for Pfizer Inc. to around $28.74, indicating potential for stock appreciation. Pfizer Inc. is currently involved in a Phase 3 trial for a new endometrial cancer treatment, which could lead to significant revenue if successful. Market sentiment has shown signs of improvement, with technical indicators suggesting a bullish trend for Pfizer Inc.'s stock. Despite recent challenges, some analysts believe Pfizer Inc. is undervalued, attracting interest from bargain-hunting investors. The current stock price is around $28, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector. Pfizer Bear Case Investors should be bearish about investing in Pfizer Inc. for these reasons: Concerns about the sustainability of dividends have arisen due to a post-pandemic slowdown in revenue growth. There is increasing pressure on Pfizer Inc. and other pharmaceutical companies from potential drug pricing reforms, which could impact profitability. Analyst ratings remain mixed, with a significant number of analysts maintaining a "Hold" rating, suggesting limited upside potential. Demand for vaccines has been declining, which may negatively affect Pfizer Inc.'s revenue from its vaccine portfolio. Recent commentary has highlighted challenges in regaining growth as older products face loss of exclusivity, raising concerns about future earnings. PFE Forecast - Frequently Asked Questions What is Pfizer's forecast for 2026? According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Pfizer is $28.61, with a high forecast of $36.00 and a low forecast of $25.00. Should I buy or sell Pfizer stock right now? 21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 3 sell ratings, 12 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PFE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PFE, but not buy additional shares or sell existing shares. Does Pfizer's stock price have much upside? According to analysts, Pfizer's stock has a predicted upside of 10.39% based on their 12-month stock forecasts. Has Pfizer been upgraded by Wall Street analysts recently? Over the previous 90 days, Pfizer's stock had 3 upgrades by analysts. What analysts cover Pfizer? Pfizer has been rated by research analysts at Argus, Bank of America, BMO Capital Markets, CICC Research, Citigroup, Guggenheim, HSBC, Morgan Stanley, Royal Bank Of Canada, UBS Group, Weiss Ratings, Wolfe Research, and Zacks Research in the past 90 days. Do Wall Street analysts like Pfizer more than its competitors? Analysts like Pfizer less than other "medical" companies. The consensus rating score for Pfizer is 2.19 while the average consensus rating score for "medical" companies is 2.30. Learn more on how PFE compares to other companies. Stock Forecasts and Research Tools Related Companies AMGN Stock Forecast GILD Stock Forecast MRNA Stock Forecast NVAX Stock Forecast ABBV Stock Forecast AZN Stock Forecast BMY Stock Forecast JNJ Stock Forecast LLY Stock Forecast MRK Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Pfizer RecommendationsWolfe ResearchWall Street ZenWeiss RatingsCitigroupRoyal Bank Of CanadaCICC ResearchUBS GroupMorgan StanleyBank of AmericaGuggenheimHSBCBMO Capital MarketsArgusZacks ResearchBarclays This page (NYSE:PFE) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pfizer Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pfizer With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
